NOTCH1 Antibody (C-term) Blocking Peptide

DETAILS

Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
Gene Id: 4851
Category: Peptides; Blocking Peptides
Subtitle: Synthetic peptide
Gene Name: NOTCH1
Other Names: Neurogenic locus notch homolog protein 1, Notch 1, hN1, Translocation-associated notch protein TAN-1, Notch 1 extracellular truncation, NEXT, Notch 1 intracellular domain, NICD, NOTCH1, TAN1
Availability: 2 weeks
Bio Background: NOTCH1 functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBP-J kappa and activates genes of the enhancer of split locus. This protein effects the implementation of differentiation, proliferation and apoptotic programs, and may be important for normal lymphocyte function. In altered form, it may contribute to transformation or progression in some T-cell neoplasms. In fetal tissues it is most abundant in spleen, brain stem and lung. NOTCH1 is also present in most adult tissues where it is found mainly in lymphoid tissues. NOTCH1 is synthesized in the endoplasmic reticulum as an inactive form which is proteolytically cleaved by a furin-like convertase in the trans-Golgi network before it reaches the plasma membrane to yield an active, ligand-accessible form. Cleavage results in a C-terminal fragment N(TM) and a N-terminal fragment N(EC). Following ligand binding, it is cleaved by TNF-alpha converting enzyme (TACE) to yield a membrane-associated intermediate fragment called notch extracellular truncation (NEXT). This fragment is then cleaved by presenilin dependent gamma-secretase to release a notch-derived peptide containing the intracellular domain (NICD) from the membrane NOTCH1 truncation is associated with T-cell acute lymphoblastic leukemia. NOTCH1 contains a putative 5 ANK repeats and 36 EGF-like domains.
Bio References: Gray, G.E., et al., Am. J. Pathol. 154(3):785-794 (1999).Matsuno, K., et al., Nat. Genet. 19(1):74-78 (1998).Ellisen, L.W., et al., Cell 66(4):649-661 (1991).
Primary Accession: P46531
Targetspecificity: The synthetic peptide sequence used to generate the antibody AP6218a was selected from the C-term region of human NOTCH1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.